Table 1 Tumor stage and treatment parameters
n=60 | WW (n=39) | TME (n=15) | LE (n=6) | |
|---|---|---|---|---|
cT | ||||
T3a | 10 (17%) | 8 (20%) | 0 | 2 (33%) |
T3b | 22 (37%) | 15 (38%) | 6 (40%) | 1 (17%) |
T3c | 9 (15%) | 6 (15%) | 3 (20%) | 0 |
T3d | 2 (3%) | 0 | 1 (7%) | 1 (17%) |
T4 | 17 (28%) | 10 (25%) | 5 (33%) | 2 (33%) |
cN+ | 49 (82%) | 30 (77%) | 15 (100%) | 4 (67%) |
Clinical stage | ||||
II | 11 (18%) | 9 (23%) | 0 | 2 (33%) |
III | 49 (82%) | 30 (77%) | 15 (100%) | 4 (66%) |
cCRM+ | 36 (60%) | 21 (54%) | 12 (80%) | 3 (50%) |
cEMVI+ | 19 (32%) | 8 (21%) | 9 (60%) | 2 (33%) |
Initial APR indication | 31 (52%) | 22 (56%) | 6 (40%) | 3 (50%) |